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Abstract
Background: Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In
non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for
an adequate treatment decision. The aim of this study is to determine the clinical and economic impact of current
anaplastic lymphoma kinase testing scenario in Spain.
Methods: A joint model, composed by decision-tree and Markov models, was developed to estimate the long-term
health outcomes and costs of NSCLC patients, by comparing the current testing scenario for ALK in Spain vs a
hypothetical no-testing. The current distribution of testing strategies for ALK determination and their sensitivity and
specificity data were obtained from the literature. Treatment allocation based on the molecular testing result were
defined by a panel of Spanish experts. To assess long-term effects of each treatment, 3-states Markov models were
developed, where progression-free survival and overall survival curves were extrapolated using exponential models.
Medical direct costs (expressed in €, 2019) were included. A lifetime horizon was used and a discount rate of 3%
was applied for both costs and health effects. Several sensitivity analyses, both deterministic and probabilistic, were
performed in order test the robustness of the analysis.
Results: We estimated a target population of 7628 NSCLC patients, including those with non-squamous histology
and those with squamous carcinomas who were never smokers. Over the lifetime horizon, the current ALK testing
scenario produced additional 5060 and 3906 life-years and quality-adjusted life-years (QALY), respectively, compared
with the no-testing scenario. Total direct costs were increased up to € 51,319,053 for testing scenario. The
incremental cost-effectiveness ratio was 10,142 €/QALY. The sensitivity analyses carried out confirmed the
robustness of the base-case results, being the treatment allocation and the test accuracy (sensitivity and specificity
data) the key drivers of the model.
Conclusions: ALK testing in advanced NSCLC patients, non-squamous and never-smoker squamous, provides more
than 3000 QALYs in Spain over a lifetime horizon. Comparing this gain in health outcomes with the incremental
costs, the resulting incremental cost-effectiveness ratio reinforces that testing non-squamous and never-smoker
squamous NSCLC is a cost-effective strategy in Spain.
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Background
Lung cancer is the leading cause of cancer death world-
wide and was responsible for the highest number of
deaths from cancer in Spain in 2018, with 22,133 deaths
[1, 2]. Non-small cell lung cancer (NSCLC) accounts for
85–90% of lung cancer cases [3]. NSCLC has various
histological subtypes, of which adenocarcinoma is the
most common. In this subtype of NSCLC, several onco-
genic and actionable drivers have been described, such
as rearrangement of the anaplastic lymphoma kinase
(ALK) gene, which is present in approximately 5% of
cases of NSCLC [4]. Other actionable mutations have
been detected in patients with NSCLC which affect the
epidermal growth factor receptor (EGFR), BRAF, ERBB2,
MET and gene fusions involving ROS1, RET or NTRK1–
3 [5]. About 70% of NSCLC patients have advanced dis-
ease at diagnosis, meaning they are not suitable for cura-
tive treatment [6]. The concept of personalized medicine
came up with the identification of predictive biomarkers
that enable the detection of patients who may obtain the
greatest benefit with least associated toxicity from treat-
ments such as chemotherapy or immunotherapy, or tar-
geted therapy based on the individual tumor profile [7].
The detection of specific genomic alterations, such as
ALK gene rearrangement in lung cancer patients, has
evolved, leading to improved new detection techniques,
and is currently considered indispensable in NSCLC for
the prognostic evaluation, clinical decision-making and
appropriate treatment [8]. Therefore, molecular genotyp-
ing at the diagnosis of advanced NSCLC is critical, since
target identification is absolutely essential to allow access
to therapies with the best efficacy and safety profile [9].
Currently, various methods allow the detection of ALK
rearrangement in NSCLC, and the choice of assay de-
pends on criteria such as personnel requirements, ana-
lytical parameters (sensitivity, specificity), associated
costs, and others [10]. Molecular alterations in ALK may
be identified by fluorescent in situ hybridization (FISH),
immunohistochemistry (IHC), real-time polymerase
chain reaction (RT-PCR), and new molecular techniques
as next-generation sequencing (NGS) and NanoString
nCounter [11, 12].
For some years, FISH has been the reference standard
for detecting tumors carrying ALK rearrangement. How-
ever, growing evidence has shown that IHC testing is an
efficient tool in the detection of ALK rearrangement,
and confirmation of positive results by FISH is no longer
needed [10, 13].
The Spanish Society of Medical Oncology (SEOM)
and the Spanish Society of Pathology (SEAP) have pub-
lished common recommendations to guide biomarker
testing in patients with advanced NSCLC according to
current evidence. ALK rearrangement should be tested
in all patients with adenocarcinoma or non-squamous
carcinoma, and also in squamous cell carcinoma in pa-
tients aged < 50 years of age and/or with low or no to-
bacco use. According to guidelines for molecular
diagnosis in advanced NSCLC patients, molecular testing
of EGFR and BRAF mutations, ALK and ROS1 rear-
rangements and programmed death-ligand 1 (PD-L1)
expression is considered mandatory [3, 14].
The main objective of this analysis was to quantify the
clinical and economic impact of the current molecular
testing scenario of NSCLC patients in Spain, focusing on
the detection of ALK rearrangement, and comparing it
with a hypothetical no-testing scenario.
Methods
A joint model combining a decision-tree with Markov
models was used to determine long-term health results
and associated costs of the molecular testing scenario of
NSCLC patients compared with a hypothetical no-
testing scenario in Spain, using Microsoft Excel 2010
(Fig. 1).
The decision-tree model considered four alternative
strategies for ALK rearrangement determination: IHC,
FISH, IHC followed by confirmation of positive results
by FISH (reflex), and NGS. If the result was invalid, the
test was repeated. If the result was interpretable, the
model determined four possible results: true positive
(TP), false positive (FP), true negative (TN), and false
negative (FN). These four possibilities reflect the typical
outcomes of a binary diagnostic test (positive or nega-
tive), the underlying prevalence of the biomarker of
interest (ALK+), and the sensitivity and specificity of the
test strategies [15]:
- True positive: Prevalence *sensitivity
- False positive: (1–prevalence) * (1–specificity)
- True negative: (1–prevalence) * specificity
- False negative: Prevalence * (1–sensitivity)
Based on the test results, a treatment was allocated
and patients entered in the respective Markov model
(in the no-testing scenario, patients enter directly into
the non-targeted therapy Markov model), which was
developed following an area under the curve structure
with three health states: progression-free survival (PFS
state), progressed-disease (PD state), and death state
(absorbent state).
The Markov models considered monthly cycles, with a
time horizon of 20 years (lifetime) and a discount rate of
3% for future costs and effects, as recommended by the
guidelines for the evaluation of health technologies in
Spain [16, 17].
The outcomes of the integrated model include life
years (LY) and quality-adjusted life years (QALYs). Total
costs (expressed in euros of 2020) were obtained from
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the health payer’s perspective, thus, direct health costs
were considered in the analysis.
A multidisciplinary group of oncologists and
pathologists, who are authors of this article, validated
the included parameters and assumptions made, as well
as the clinical feasibility of the results.
Target population
A hypothetical cohort of patients with advanced or
metastatic NSCLC, who were candidates for first-line
treatment according to the molecular diagnosis, was in-
cluded in the model. Following the current clinical
guidelines for molecular diagnosis in lung cancer [14],
both patients with non-squamous histology and those
with squamous NSCLC who were never smokers were
considered . Table 1 shows the estimation of the target
population based on the literature [3, 18–22].
Decision-tree parameters
Table 2 lists all inputs specific to the decision-tree
model.
Current distribution in Spain of the four ALK
determination strategies included in the model (Fig. 1)
was obtained from the analysis of the LungPath
Fig. 1 Model diagram. ALK: anaplastic lymphoma kinase IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; NGS: next-generation
sequencing; TP: True positive; FP: false positive; TN: true negative; FN: false negative; EGFR:epidermal growth factor receptor; WT: wild-type; TPS: tumor
proportion score TKI: tyrosine kinase inhibitors; PFS: progression-free survival PD: progressed-disease. a Chemoterapy: cisplatin+pemetrexed;
carbolplatin+paclitaxel+bevacizumab; cisplatin+pemetrexed+pembrolizumab
Table 1 Estimated target population
% Reference N
1 Patients with lung cancer in 2020 (18) 28,475
2 Patients with NSCLC 85.0% (3) 24,204
3 Stage VI in samples of NSCLC patients 54.5% (19) 13,191
4 Patients with stage IV NSCLC non-squamous subtype 66.9% (20) 8825
5 Patients with stage IV NSCLC squamous subtype 33.1% (20) 4366
6 Patients with stage IV NSCLC squamous subtype, never smokers 16.0% (21) 699
7 Candidate for ALK rearrangement diagnosis (steps 4 + 6) 9523
8 Patients finally tested for ALK (testing rate) 80.1% (22) 7628
NSCLC Non-small cell lung cancer, ALK anaplastic lymphoma kinase
Nadal et al. BMC Cancer          (2021) 21:689 Page 3 of 13
database, as was the prevalence of positive results for the
biomarkers of interest (positivity rate) [22].
In some cases, due to a lack of sample material or
insufficient tumour cell percentage, it was not possible
to accurately determine the test result and it was
considered invalid, being a rebiopsy necessary
sometimes. It was considered that in 77.1% of the invalid
results a rebiopsy was carried (especially when patients
were asymptomatic) waiting for results before starting
treatment [24]. In the remaining 22.9%, chemotherapy
was initiated without a molecular diagnosis result. It was
assumed that the percentage of invalid results would be
the same when the determination of ALK was made
with IHC or FISH, but not with NGS, where the
percentage of invalid tests may be higher [23].
The specificity and sensitivity parameters of each
testing technique were obtained from Marchetti et al.
for IHC [25] and for FISH [26]. The first article reports
data from the European Quality Assessment in Italy,
while the second analyzed 1031 samples using IHC, with
FISH as the reference technique, and discrepancies
analyzed by NGS. For NGS, 100% of specificity and
sensitivity was assumed, as it is considered the gold
standard in the determination of ALK.
The specific costs of the decision-tree were the costs
of the tests used for molecular diagnosis and the cost of
biopsy (applied when rebiopsy was required). The costs
of the tests were agreed by the expert panel: € 60.28 for
IHC; € 111.36 for FISH; € 475 for NGS; € 165 for the
EGFR test; €100 for the ROS1 test; and € 130 for the
PD-L1 test. For the biopsy, a cost of € 411.22 was con-
sidered [27].
Depending on the molecular testing result, a specific
treatment was assigned (Fig. 1). Since the analysis is
focused on ALK testing, when patients entered the
Markov models, it was necessary to differentiate whether
the positive result for ALK was a TP or a FP and
whether the negative result was a TN or a FN. TP was
differentiated from FP, as treatments targeting ALK
(alectinib/crizotinib) are not effective in patients without
ALK rearrangement, and therefore these treatments in
patients who are FP for ALK provides almost no benefit.
In the case of negative tests, it was assumed that in FN
patients (who were ALK+ actually), the determination of
EGFR and ROS1 would be negative, assuming that the
concurrency of more than one mutation in ALK and
EGFR or ROS1 is very infrequent [22].
Markov model parameters
Eleven possible first-line treatments were considered,
allocated according to the molecular diagnosis, entered
the Markov models (one for each treatment) (Table 3).
The distribution of treatments within the same molecu-
lar target was established by the panel of experts, reflect-
ing current clinical practice in Spain.
Since the time horizon of the analysis was longer than
the observation periods in clinical trials, it was necessary
to extrapolate PFS and overall survival (OS) data, to
obtain curves that allow to model transition between











PD-L1≥ 50% 33% [18]
Percentage of invalid results
With IHC or FISH 2.6% [18]
With NGS 3.4% [19]
Rebiopsy
Probability of rebiopsy if invalid 77.1% [20]
Specificity and sensitivity
IHC 97.9% / 96.8% [21]
FISH 99.8% / 90.9% [22]
NGS 100% Assumptiona
ALK anaplastic lymphoma kinase, IHC immunohistochemistry, FISH fluorescent
in situ hybridization, NGS next-generation sequencing, EGFR epidermal growth
factor receptor
aConsidered the gold standard in the determination of ALK






ALK+ Alectinib 89.38% 80%
Crizotinib 10.63% 20%




ROS1+ Crizotinib 100% 100%
WT TPS 50% Pembrolizumab 100% 100%
TPS < 50% Cisp + pmtrx 30.00% 40.0%
Carb+ paclitx + bev 10.00% 5.0%
Cisp + pmtrx + pembro 60.00% 55.0%
ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, WT
wild-type, TPS tumor proportion score, Cisp cisplatin, Carb carboplatin, pmtrx
pemetrexed, paclitx paclitaxel, bev bevacizumab, BC Base case, SA
sensitivity analysis
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health states. In the absence of individualized patient
data for each treatment, it was decided to use
exponential models based on the median PFS and OS
reported in the respective studies. In the recent update
of the ALEX trial [28], used to obtain PFS and OS
median for alectinib and crizotinib, median OS in the
alectinib group was not reached, so extrapolation
curves were obtained from the cost-effectiveness
model of alectinib (data on file). Median PFS and OS
for EGFR-targeted therapies were obtained from the
FLAURA study [29, 30], and for ROS1-targeted ther-
apies from PROFILE 1001 [31]. For wild-type (WT)
patients treated with pembrolizumab in monotherapy,
median PFS and OS were obtained from KEYNOTE-
024 [32, 33], while from WT patients with tumor
proportion score (TPS) < 50% median PFS and OS for
the tree treatment strategies considered in the model
were obtained from PARAMOUNT [34], Sandler
et al. [35] and KEYNOTE-189 [36, 37].
Some adjustments had to be made in the PFS and OS
exponential curves in the case of FP in ALK. The expert
panel considered that most patients will have shown
progression at the first follow-up visit and all of them
will have progressed in the second visit. Based on this, a
median of 2 months was assumed for the PFS in these
patients, applying a stopping rule at 6 months (all pa-
tients progressed by then). Concerning OS, where there
are more factors to consider, such as subsequent therap-
ies, a median of 18 months was assumed.
The specific costs of the Markov models were the
drug acquisition costs (both first-line and subsequent
treatments) and the administration costs of intravenous
treatments. Drug costs are expressed as the wholesale
price considering the corresponding deductions accord-
ing to Royal Decree-Law 08/2010 [38, 39]. For drugs
where the dose depends on the patient characteristics, a
mean body surface area of 1.81 and a mean weight of
72.885 kg was used [40]. Vial sharing for intravenous
treatments was assumed.
Concerning intravenous administration costs, a cost
of € 211 was considered (corresponding to day
hospital visit) [27].
The model also included the cost of subsequent
treatments (once patients progressed after first-line
treatment and transit to the PD state). To avoid uncer-
tainty regarding subsequent treatments and simplifying
the model, only second-line treatments were considered.
The percentage of patients receiving an active second-
line treatment or who would receive best supportive care
(BSC) was determined by the panel of experts, and as
was the selection of the most representative second-line
treatment (based on the first-line treatments received).
The median PFS for second-line treatments was ob-
tained from the literature [41–47]. All these parameters
of the subsequent treatments are shown in an additional
file [see Additional file 1].
The model incorporated utility values of 0.814 for PFS
state, and 0.725 and 0.470 for the PD state with and
without active treatment, respectively [48].
Sensitivity analysis
To assess the uncertainty of some variables used in the
analysis and to determine the robustness of the model
and the results obtained, both deterministic and
probabilistic sensitivity analyses (PSA) were performed.
Scenario analysis
Alternative scenarios to the base case were performed,
modifying some assumptions, or exploring methodological
alternatives.
– Target population scenarios: only patients with
adenocarcinoma; and increasing the testing rate
progressively (85% year 2 and 90% year 3).
– Time horizon: 10, 5 and 3 years, instead of lifetime
(fixed at 20 years).
– Decision-tree scenarios: sequential rather than
parallel diagnoses, and scenarios reducing invalid
tests in IHC and FISH to 1% (not in NGS) and with
0% invalid tests in all options (IHC, FISH and NGS).
– Markov-model scenarios: alternative treatment
allocation (Table 3), adjustments in the FP response
for ALK (variations in PFS medians (1.5–3) and OS
(15–21); and no stopping rule at 6 months), and
without considering the cost of subsequent
treatments.
Univariate analysis (one-way sensitivity analysis)
Some model variables were individually modified by 10%
or 20% (depending on the uncertainty associated with
the variable) with respect to the base case.
Bivariate analysis
Given the uncertainty associated with these variables, a
specific analysis was performed where the sensitivity and
specificity of IHC and FISH were simultaneously
modified by ±1%, ± 2%, ± 3%, etc.
PSA
1000 simulations were performed using second-order
Monte Carlo methodology, simultaneously modifying all
model variables using a given distribution, in line with
reported recommendations [49]. Utility values were
modified using a beta distribution. For the body surface
area and weight, the median PFS and OS, the positivity
rate, the percentage of invalid results, and the probability
of rebiopsy when results are invalid, a normal
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distribution was used. All unit costs were modified ac-
cording to a gamma distribution.
Results
The costs and health outcomes obtained from the
Markov models analyzed independently of the allocation
between testing methods in the decision-tree, provided
the mean cost as the mean QALYs per-patient according
to the test result (Fig. 2). These results provide an as-
sessment of costs and health outcomes per-patient, re-
gardless of the technique used to obtain the TP, FP, TN
and FN test outcome.
TP patients correctly treated with ALK-targeted ther-
apies shown the best health outcomes, which also led to
higher costs, as they spent more time in the PFS state
while being treated with alectinib or crizotinib. FP pa-
tients had the worst health outcomes and the lowest
cost, as they quickly progressed to second-line receiving
few cycles of alectinib or crizotinib.
Table 4 lists the results of the base case, showing the
total health outcomes and costs for the current testing
scenario and the non-testing scenario, including the in-
cremental results comparing both scenarios.
The current strategy of testing patients with
advanced NSCLC provided a gain of 3907 QALYs
compared with the no-testing scenario, over a 20-year
time horizon. This also entailed higher costs, includ-
ing those of the tests themselves, but mainly due to
the cost of targeted treatments. The comparison of
costs and health outcomes through the incremental
cost-effectiveness ratio (ICER), shows that the current
ALK testing strategy in Spain is cost-effective, as it
was below the cost-effectiveness thresholds commonly
considered in Spain [50, 51].
Sensitivity analysis
The target population scenarios affect only the absolute
value of the results (in both scenarios compared),
maintaining the ICER constant. If only patients with
adenocarcinoma were tested, only 3620.06 QALYs
would be gained (287 fewer QALYs gained than in the
base case). In the scenario where the testing rate was
increased up to 90% after 2 years, the gain in QALYs
compared with the non-testing scenario would be
4389.48 QALYs (483 more than in the base case).
Shorting time horizon up to 10, 5 and 3 years,
increased the ICER to € 14,223, €16,360, and € 17,275/
QALY, respectively.
The decision-tree scenarios had a slight influence on
the results, and only affected the current testing scenario
(the non-testing scenario remained the same). A sequen-
tial instead of a parallel diagnosis slightly decreased the
costs of the current testing scenario (€ -391,375), and
the ICER was reduced to € 13,036/QALY. Reducing the
percentage of invalid tests also hardly impacted on the
ICER (€ 13,139 and € 13,140 /QALY for the two scenar-
ios posed, respectively).
The Markov model scenarios had the greatest
influence on the base case results. When the allocation
of treatments shown in Table 3 was modified, the ICER
increased to € 24,660/QALY, mainly due to the total
cost for a lifetime horizon of the non-testing scenario
being reduced from € 806,959,058 to € 749, 855,143
(€-57,103,915), while in the current testing scenario it
was only reduced by € 6,911,633. The adjustments in the
response to FP for ALK only affected the current testing
scenario, although the changes respect to the base case
were minimal (± 0.01% with respect to costs and
QALYs). The ICER resulting from modifying the PFS
Fig. 2 Mean results per patient. TP: True positive; FP: false positive; TN: true negative; FN: false negative
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and OS in FP patients, or not considering the 6-months
stopping rule were € 13,134, €13,137, and € 13,148/
QALY, respectively. Not considering second-line treat-
ments reduced the ICER to € 10,059/QALY, due to a re-
duction of € 58,666,678 and € 46,645,461 in the total
costs of the current and non-testing scenarios,
respectively.
The results of the univariate analysis, where the
impact of the extreme values of each variable on the
base case incremental cost-utility ratio (ICUR) and are
assessed, are represented by a tornado diagram in Fig. 3.
Patient characteristics (mean weight and body surface
area), discount rate (for both cost and effects), and
prevalence of EGFR+ shown the greatest impact on base
case results (Fig. 3a). The tornado diagram represented
in Fig. 3b detailed the analysis of the second-line costs.
In the bivariate analysis, the specificity and sensitivity
base case parameters are increased and decreased
simultaneously, and Table 5 shows how the 3907
QALYs gained in the base case are modified accordingly.
The gradient from green to red shows the difference
from the base case.
Figure 4 shows the PSA results represented by an
incremental cost-effectiveness plane. The means ob-
tained from the 1000 simulations (€ + 51,319,053 and
3907 QALYs gained with respect to the non-testing
scenario) are in line with the deterministic results in
Table 4.
Discussion
In recent years there have been multiple changes in the
approach to lung cancer treatment and, in particular, to
NSCLC, including the identification of biomarkers that
allow treatment selection in some subgroups of patients
with advanced disease [52]. Deciding which biomarkers
and which subgroup of patients should be tested is
clinically relevant, and it must be assessed at diagnosis,
since the first treatment a cancer patient receives should
be the most effective according to their clinical and
molecular features [52].
Specifically, the detection of ALK rearrangements in
patients with NSCLC provides unquestionable clinical
benefits. A systematic review and meta-analysis by Elliott
et al. [53] concluded that, ALK inhibitors improved PFS
relative to chemotherapy. Also, treatment-related deaths
were found to be infrequent among ALK-positive NSCL
C patients [53]. Molecular testing for these rearrange-
ments (along with molecular alterations in other bio-
markers) is considered mandatory in all patients with
non-squamous NSCLC or patients with squamous
NSCLC younger than 50 years or with low tobacco ex-
posure, according to the current clinical guidelines [14,
54, 55]. Next-generation ALK tyrosine kinase inhibitors
(TKI) have generally replaced crizotinib, the first-
generation TKI, as front-line treatments for patients
with ALK-positive NSCLC [28]. Alectinib was associated
with longer PFS and lower toxicity than crizotinib and
showed activity against central nervous system (CNS)
disease in patients with ALK-positive NSCLC [56].
Pathology departments must work in coordination
with the other services involved in the diagnosis and
treatment of NSCLC patients and are key to optimizing
the available resources and the clinical management of
these patients [52]. Therefore, to evaluate the efficiency
of the management of patients with advanced NSCLC in
Spain, a comprehensive approach to molecular diagnosis
in conjunction with pharmacological treatment is
essential.
Our study is the first one that uses this comprehensive
approach to assess the long-term clinical and economic
impact of the current molecular testing scenario in
Spain. The Markov models allow the calculation of long-
term costs, LYs, and QALYs for each treatment that is
allocated based on the molecular result, and together
with the positivity rate of each biomarker, the mean cost
as the mean QALYs per patient were calculated. The TP
patients provide, by far, the best health outcomes while
the FP represented the worst health outcomes, therefore
specificity and sensitivity have great importance. Bivari-
ate analysis showed that when specificity and sensitivity
were decreased equally (in the same percentage), gained
QALYs were slightly lower with the decreased specificity
than with the decreased sensitivity. Complementing the
Markov models, the decision tree model allows to
Table 4 Base case results
Current scenario tested No-testing Difference
Cost of testing € 3,613,701 € 0 € + 3, 613, 701
Cost of treatment € 854,664,411 € 806,959,058 € + 47, 705, 353
Total costs € 858,278,111 € 806,959,058 € + 51, 319, 053
LY 21.233,59 16.173,45 + 5060.14
QALYs 14.654,68 10.748,05 + 3906.64
ICER (€/LY gained) € 10,142/LY
ICUR (€/QALY gained) € 13,136/QALY
LY life years, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio
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compare between the current molecular testing scenario
(considering 4 alternative strategies for ALK rearrange-
ment determination, IHC, FISH, reflex, and NGS) and
the no-testing scenario. The ICER obtained (both base
case and sensitive analysis) confirms that determining
ALK rearrangement in patients with advanced NSCLC is
a cost-effective strategy, since it is below the cost-
effectiveness thresholds usually considered in Spain [50,
51]. Therefore, our findings support and confirm the
recommendations of national guidelines [14]. Prelim-
inary results of our study were presented in ISPOR
2020 in the form of poster [57] and 2020 World
Conference on Lung Cancer (WCLC) through an oral
communication” [58].
The described comprehensive approach has also been
used in other economic assessments. Lee et al. published
a generalized model that allows the evaluation of
molecular diagnosis and subsequent targeted therapy
[59]. Using this generalized model, the same author
determined the cost-benefit ratio of ALK testing using
different techniques for subsequent targeted treatment
with crizotinib. The authors concluded that more than
95% of the total cost corresponded to the treatment and,
therefore, the model was particularly sensitive to the
Fig. 3 Tornado diagrams. ICUR: incremental cost-utility ratio
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price or clinical benefits of crizotinib and the accuracy
of the diagnostic test, but was not particularly impacted
by the cost of the diagnostic test [59].
Other studies have been based on similar approaches
to compare ALK rearrangement detection techniques.
Doshi et al. [10] concluded that both in the United
States (U.S.) and Europe, ALK testing only by IHC is the
lower-cost strategy compared with using only FISH, re-
flex testing, or performing both tests in parallel. Paolini
et al. [13] assessed the clinical and economic benefits of
using IHC for ALK rearrangement testing in Italy, and
concluded that increased use of D5F3 would provide
Table 5 Bivariate analysis
BC Base case, IHC immunohistochemistry, FISH fluorescent in situ hybridizatio
Fig. 4 PSA results. Incremental cost-effectiveness plane. QALY: quality-adjusted life years
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savings of € 468,000, due to its lower acquisition cost
compared with FISH and a comparable detection rate.
Lu et al. [60] evaluate the cost-effectiveness of the ALK
tests followed by crizotinib compared to the standard
chemotherapy in advanced NSCLC from the Chinese
healthcare system perspective. They found that two test-
ing methods for ALK assessed (NGS and multiplex PCR)
followed by subsequent crizotinib treatment, are both
cost-effective compared to standard chemotherapy with-
out ALK testing [60]. Also, two recent analyses have fo-
cused on the cost-effectiveness of using NGS in NSCLC
patients, finding that this technology would be cost-
effective compared to single testing [61, 62].
Unlike these economic assessments, our analysis is not
intended to compare diagnostic tests, the aim is to
analyze the current scenario of molecular testing in
Spain for patients with NSCLC, quantify the costs and
long-term health outcomes, and compare them with a
hypothetical non-testing scenario.
The study with the most similar objective was
performed by Loubiére et al. [63], although the
methodology differs entirely, as it prospectively
evaluated a cohort of 843 patients in 19 French
hospitals, while our analysis is based on a theoretical
pharmacoeconomic model. Interestingly, their results
were similar to our findings, since they reported that the
“at least one biomarker status known” strategy is cost-
effective compared with the “no biomarker testing” strat-
egy, with an ICER of € 13,230 per QALY gained, while
our base case ICER was 13,136 per QALY gained [63].
Our study has some limitations. First, the limitations
inherent to pharmacoeconomic models, which are
characterized by some degree of structural rigidity which
cannot completely recapitulate the complexity of the
clinical practice. For example, reproducing the
pathological and molecular diagnosis process accurately
is complicated, due to the complexity of the process and
the high variability of the studies identified. Therefore,
to simplify the model we did not include the pre-
analytic phases in our study. Although turnaround times
are a key factor in initiating treatment at an appropriate
time, no evidence has been found regarding their influ-
ence on the treatment effectiveness, and therefore the
time from diagnosis to initiation of treatment was not
included as a variable in our model. As stated in the lit-
erature and confirmed by the expert panel, turnaround
times may vary from 2 to 5 [10] to 6–12 working days
[64], with significant variations between centers (diag-
nostic outsourcing may add 1 week to the turnaround
time according to the experts). A study designed to es-
tablish whether reducing the turnaround time could re-
duce the healthcare resources utilization and could
improve the results obtained in this analysis would be of
interest.
Secondly, in the molecular diagnosis phase, the
percentage of invalid results and the specificity and
sensitivity parameters of each technique were obtained
from the literature, in the absence of a specifically
designed study that could provide these data together.
The definition of an invalid result may vary between
studies and rely on the reference technique used to
calculate the specificity and sensitivity. The studies
published by Marchetti et al. [25, 26] were selected by
the expert panel, since based on these parameters of
specificity and sensitivity, the model predicted similar
results to those observed in current clinical practice.
Similarly, although the experts agreed that 2.6% of the
invalid tests reported in LungPath study would apply
equally to IHC and FISH, usual practice shows
significant variations according to the histology and
between reference and smaller centers, where pre-
analytical conditions may lead to a higher failure rate
when using FISH. For NGS, a higher percentage of in-
valid results has been reported, as it is a newer technique
and is of greater difficulty in the pre-analytic phase, and
is more likely that samples will not have enough quantity
or quality for NGS testing.
In addition, the percentage of invalid results could also
be reduced in the future through the increased use of
liquid biopsies. Liquid biopsy is a novel powerful tool for
tumor genotyping and multiple levels of evidence
support its use as an alternative strategy for molecular
testing in advanced NSCLC, especially when tumor
tissue is not sufficient [65].
Thirdly, the clinical management of patients with
NSCLC reproduced by the Markov models also has
some limitations. A lifetime horizon was adopted, as this
made it possible to capture all the benefits of the
targeted therapies in terms of LY and QALYs gained, in
line with the economic evaluation developed by Lee
et al. [57] which was based on the cost-effectiveness ana-
lysis of crizotinib. However, sensitivity analyses of the
time horizon showed that determining ALK rearrange-
ment remained cost-effective as compared with the non-
testing strategy. Due to the lack of individualized patient
data for each treatment, the utilization of exponential
parametric models (adjusted according to the median
PFS and OS) was assumed. This assumption, validated
by the panel of experts, is in line with published eco-
nomic assessments of alectinib [48, 66], where the expo-
nential models showed the best fit to the ALEX study
data. Since our analysis focused on molecular testing of
patients with advanced NSCLC and the consequent
first-line of treatment, the subsequent lines (second-line)
only show the influence in economic terms, were intro-
duced in the model as a one-off cost.
Fourthly, concerning costs, it is difficult to set the real
price of diagnostic tests, since there are wide variations
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between centers, and in many cases, the cost is borne by
research funds or by pharmaceutical companies since
they are not reimbursed by the Spanish National Health
System. Besides, as the analysis focused on the
determination of ALK, not all the benefits of using NGS,
which allows to evaluate simultaneously multiple
biomarkers instead of testing each biomarker one at a
time, cannot be captured. An economic assessment of
the use of NGS instead of testing individually the main
biomarkers will require a specifically designed model
and is beyond the scope of this work.
To overcome or minimize these limitations and the
associated uncertainty, we performed sensitivity analyses
that confirmed the robustness of the results obtained. In
addition, all assumptions made, the parameters
considered, and the results obtained were validated by
the panel of experts.
Conclusions
In conclusion, our analysis shows that the detection of
ALK rearrangements in patients with NSCLC in Spain
provides important clinical benefits compared with not
testing in these patients. Appropriate ALK testing yields
about 4000 QALYs gained over a 20-year time horizon.
When these results are compared with the incremental
cost, the resulting ICER shows that the current molecu-
lar testing strategy in Spain not only increases and
improves the lives of patients with NSCLC but is also
cost-effective for the Spanish National Health System.
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